ArticleInternational journal of clinical and experimental pathology2018
Role of CA19-9 in the prognostic evaluation of SOX neoadjuvant chemotherapy for gastric cancer.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study.Journal of clinical medicine · 2026Article
- Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment.BMC gastroenterology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNeoadjuvant chemotherapy refers to systemic chemotherapy applied before local surgery or radiotherapy for malignant tumors. The level of certain tumor markers is an important indicator for assessing the efficacy of neoadjuvant chemotherapy. This study aimed to investigate the effect of serum CA19-9 levels on subsequent neoadjuvant chemotherapy in the treatment of gastric adenocarcinoma.
methodsWe collected 86 advanced gastric adenocarcinoma patients from January 2016 to May 2018. Patients received at least 2 cycles neoadjuvant chemotherapy with SOX (Oxaliplatin, S-1) before surgery. Effective chemotherapy was defined as producing CR or PR andineffective was defined as SD or PD. We analyze the role of serum CA19-9 level in predicting the effectiveness of neoadjuvant chemotherapy in patients with advanced gastric cancer.
resultsIn total 86 patients, 28 patients had abnormal and 58 patients had normal serum CA19-9 levels. The positivity rate of pretreatment serum CA19-9 was higher when PR or CR was achieved (P=0.0005***). The area under the ROC curve (AUC) for CA19-9 levels was 0.720 (95% CI 0.610-0.829) (P=0.001**).
conclusionsMeasurements of CA19-9 may be helpful in monitoring the efficacy of neoadjuvant chemotherapy in the treatment of patients with advanced gastric cancer and also may be able to effectively predict this effect, thereby reducing unnecessary chemotherapy.
Indexed as
Identifiers
31949620PMC6963008W3014714780What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.